Innovative CAR-T-Cell Therapy with YESCARTA (R): Gilead concludes an Outcome-based Discount Contract with the German Health Insurance Companies for the Drug YESCARTA (R) produced by Kite

首页> 外文期刊>Oncology research and treatment. >Innovative CAR-T-Cell Therapy with YESCARTA (R): Gilead concludes an Outcome-based Discount Contract with the German Health Insurance Companies for the Drug YESCARTA (R) produced by Kite

【24h】

Innovative CAR-T-Cell Therapy with YESCARTA (R): Gilead concludes an Outcome-based Discount Contract with the German Health Insurance Companies for the Drug YESCARTA (R) produced by Kite

机译：与yescarta（r）的创新的Car-t细胞疗法：Gilead将基于结果的折扣合同与德国健康保险公司进行了结论，该公司是由风筝制作的yescarta（r）的药物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2019年第8期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Innovative CAR-T-Cell Therapy with YESCARTA (R): Gilead concludes an Outcome-based Discount Contract with the German Health Insurance Companies for the Drug YESCARTA (R) produced by Kite [J] . Oncology research and treatment. . 2019,第7a8期

机译：与yescarta（r）的创新的Car-t细胞疗法：Gilead将基于结果的折扣合同与德国健康保险公司进行了结论，该公司是由风筝制作的yescarta（r）的药物
2. Very Low Frequency of Drug Therapy of Alcohol Dependence in Germany - Analysis of Data of A Statutory Health Insurance [J] . Scherbaum Norbert, Holzbach Ruediger, Stammen Gunnar, Pharmacopsychiatry . 2020,第1期

机译：德国酒精依赖的药物治疗非常低的频率 - 法定健康保险数据的分析

Innovative CAR-T-Cell Therapy with YESCARTA (R): Gilead concludes an Outcome-based Discount Contract with the German Health Insurance Companies for the Drug YESCARTA (R) produced by Kite

著录项

相似文献

相关主题

期刊订阅